NCT02483104已完成1 期
A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
AbbVie3 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2015年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 3
- 主要终点
- Number of participants with Dose-limiting toxicities
研究概览
简要总结
This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed epithelial ovarian, fallopian tube or primary peritoneal carcinoma the International Federation of Gynecology and Obstetrics (FIGO) Stage IC - IV with either optimal (< 1 cm residual disease) or suboptimal residual disease.
- •Participants must be newly diagnosed, chemotherapy-naïve, and entered between 1 and 12 weeks after initial cytoreductive surgery.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 -
- •Adequate organ and marrow function.
- •Ability to swallow and retain oral medication, and no uncontrolled emesis.
- •Women of childbearing potential (except vasectomized partner of female subjects) must agree to use adequate contraception prior to study entry, for the duration of study participation and up to 3 months following completion of therapy. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the study entry. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
排除标准
- •A history of another invasive cancer within the past 3 years, except non-melanoma skin cancer or in situ malignancies that are considered cured by the investigator (e.g., cervical cancer in situ, in situ carcinoma of the bladder, or breast carcinoma in situ).
- •Participants who received prior radiotherapy to any portion of the abdominal cavity or pelvis.
- •Participants who received prior chemotherapy for any abdominal or pelvic tumor.
- •Any investigational agents less than 4 weeks prior to study enrollment.
- •Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study enrollment.
- •Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
- •Patients with history or evidence upon physical examination of central nervous system disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of the first date of treatment on this study.
- •Prior therapy with a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.
- •Subject has a clinically significant uncontrolled condition(s), including but not limited to:
- •Uncontrolled seizure disorder, or focal or generalized seizure within the last 12 months;
- •Active infection that requires parenteral antibiotics;
- •Known active hepatitis B or hepatitis C with abnormal liver function test or organ dysfunction;
- •Symptomatic congestive heart failure; unstable angina pectoris; serious ventricular cardiac arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication (this does not include asymptomatic atrial fibrillation with controlled ventricular rate); or myocardial infarction within the last 6 months;
- •Uncontrolled hypertension (sustained systolic blood pressure > 150 mmHg or diastolic pressure > 100 mmHg despite optimal medical management);
- •Bowel obstruction or gastric outlet obstruction;
- •Psychiatric illness/social situations that would limit compliance with study requirements;
- •Any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicities.
- •Pregnant or lactating.
研究组 & 干预措施
veliparib (ABT-888)
Experimental
干预措施: carboplatin (Drug)
veliparib (ABT-888)
Experimental
干预措施: veliparib (Drug)
veliparib (ABT-888)
Experimental
干预措施: paclitaxel (Drug)
结局指标
主要结局
Number of participants with Dose-limiting toxicities
时间窗: During the first cycle (21 days) of veliparib administration
次要结局
- Maximum observed plasma concentration (Cmax) of Veliparib(For 24 hours following veliparib dosing.)
- The time to Cmax (peak time, Tmax) of Veliparib(For 24 hours following veliparib dosing.)
- Number of participants with adverse events(Approximately 5 months)
- Preliminary tumor response(Participants will be evaluated for 5 months.)
- The area under the plasma concentration-time curve (AUC) of Veliparib(For 24 hours following veliparib dosing.)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsSolid TumorsNCT01617928AbbVie (prior sponsor, Abbott)12
已完成
1 期
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT01063816AbbVie (prior sponsor, Abbott)79
撤回
1 期
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorFunctional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMetastatic Adrenal Gland PheochromocytomaMetastatic Carcinoid TumorMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2BMultiple Endocrine Neoplasia Type 1Merkel Cell CarcinomaNon-Functional Pancreatic Neuroendocrine TumorPancreatic GlucagonomaPancreatic InsulinomaRecurrent Adrenal Cortex CarcinomaNeuroendocrine NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Merkel Cell CarcinomaSomatostatin-Producing Neuroendocrine TumorStage III Adrenal Cortex CarcinomaStage III Thyroid Gland Medullary CarcinomaStage IIIA Merkel Cell CarcinomaStage IIIB Merkel Cell CarcinomaStage IV Adrenal Cortex CarcinomaStage IV Merkel Cell CarcinomaStage IVA Thyroid Gland Medullary CarcinomaStage IVB Thyroid Gland Medullary CarcinomaStage IVC Thyroid Gland Medullary CarcinomaThymic Carcinoid TumorVIP-Producing Neuroendocrine TumorWell Differentiated Adrenal Cortex CarcinomaZollinger Ellison SyndromeNCT02831179Vanderbilt-Ingram Cancer Center
已完成
1 期
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerAdult Solid NeoplasmPeritoneal CarcinomatosisRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT01264432National Cancer Institute (NCI)34
已完成
3 期
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNCT02106546AbbVie970